Special Issue "The Quest for the Sweetspot in Antithrombotic Treatment"
A special issue of Hearts (ISSN 2673-3846).
Deadline for manuscript submissions: 1 August 2020.
Interests: interventional cardiology; basic science; acute cardiac care; acute heart failure; risk factors and prevention
Interests: apoptosis; clinical cardiology; heart failure; hypertension; cell culture; ELISA; echocardiography; flow cytometry; atrial fibrillation; atherosclerosis
Special Issues and Collections in MDPI journals
This Special Issue dives right into the heart of cardiology. Our speciality is full of interventional advancements in vascular medicine, electrophysiology, coronary heart disease and structural heart disease. Also, cardio-metabolic syndrome has become an epidemic in both developed and developing countries, putting primary prevention back into the spotlight.
However, what would interventional cardiology be without the support of medical antithrombotic treatment?
Modern stents in high-risk patients prone to both thrombotic complications but also bleeding risk warrant individualised and tailored medical antithrombotic strategies. Researchers need to evaluate the effects of novel potent antithrombotic medications and varying durations of triple and dual antiplatelet therapy. Also, the outcomes of structural and valvular interventions could be improved by specific management strategies searching for the sweet-spot between thrombotic and bleeding complications. The management of peri-interventional and post-interventional antithrombotic treatment in electrophysiologic interventions warrants further investigations. In primary prevention, aspirin is no longer unrestrictedly recommended. However, there might be patients suffering from cardio-metabolic syndrome at high risk for thrombotic complications and we detecting and treating these patients accordingly could improve outcomes.
Both experimental and clinical studies evaluating cellular responses, biomarkers and clinical outcomes of established and novel antithrombotic medications and innovative interventions are welcome to this Special Issue. Also, cardiology enjoys a very active research community and is an ideal field for structured reviews and meta-analyses summing up available evidence.
We invite researcher from around the world to submit their research investigating antithrombotic and antiplatelet strategies in primary prevention, in ischemic heart disease as well as in patients after a valvular and structural cardiac intervention to our Special Issue.
Dr. Bernhard Wernly
Prof. Dr. Michael Lichtenauer
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hearts is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- atrial fibrillation